Reach Us +44 1467840001

A Concise Review Based on Analytical Method Development and Validation of Glimepiride in Bulk and Marketed Dosage Form

Pritam Jain*, Ansari Shoaib Ahmed Ayaz Ahmed, Patil Vrushali Ashok, Pawara Champalal Tersing, Sanjay Surana

R.C. Patel Institute of Pharmaceutical Education and Research, Shirpur, India.

Corresponding Author:
Pritam Jain
R.C. Patel Institute of Pharmaceutical Education and Research, Shirpur, India.
Visit for more related articles at Der Chemica Sinica


Glimepiride is a long acting Sulfonylurea imitative has its place to third generation sulfonylurea. It finds its application in the management of non-insulin contingent Type 2 diabetes mellitus and it is having a medium to long acting antidiabetic activity. For the persistence of clinical and pharmaceutical analysis, fruitful analytical procedures are obligatory to study quality control, pharmacodynamics and pharmacokinetic properties and stability studies as well. There are plenty of articles which have already been published describing analytical methods and method validation for the same. In present review account, the disclosed analytical methods are outlined for the establishment of Glimepiride in its pharmaceutical preparations and biological matrices. Most frequently used techniques such as spectrometric and liquid chromatographic methods are summarized in present review. Spectrometric methods for Glimepiride alone and in combination include parameters like λ max, solvent, matrix etc. and HPLC methods for Glimepiride alone and in combination including parameters like matrix, stationary phase, mobile phase composition detection wavelength etc. HPTLC methods including parameters like stationary phase, mobile phase combination, RF etc.


Glimepiride, UV Spectrophotometric, HPLC, HPTLC, LC-MS/MS


MET: Metformin; PIO: Pioglitazone; DAPA: Dapagliflozin; ROSI: Rosiglitazone; VOG: Voglibose; RAM: Ramipril; ATR: Atorvastatin; GLIC: Gliclazide; FLU: Fluoxetine; λ max: Wavelength Maxima; LIN: Linearity; FR: Flow Rate; RT: Retention Time; RF: Retention Factor; UV-VIS: UV/Visible Spectrophotometry; HPLC: High Performance Liquid Chromatography; RP-HPLC: Reverse Phase Liquid Chromatography; HPTLC: High Performance Thin Layer Chromatography; LC-MS/MS: Liquid Chromatography Mass Spectrometry/Mass Spectrometry; UPLC-MS/MS: Ultra Pressure Liquid Chromatography-Mass Spectrometry-Mass Spectrometry; ODS: Octadecyl Silane; KH2PO4: Potassium Dihydrogen Phosphate; OPA: Orthophosphoric Acid; IUPAC: International Union of Pure and Applied Chemistry; ATP: Adenosine Triphosphate; Ca2+: Calcium2+; IP: Indian Pharmacopoeia; Cm; Centimetre; mm: Millimetre; nm: Nanometre; μL: Micro Litter; μg: Microgram; REF: Reference; DMF: Dimethylformamide; NaOH: Sodium Hydroxide; KOH: Potassium Hydroxide; ACN: Acetonitrile; MeOH: Methanol; EtOH: Ethanol; GAA: Glacial Acetic Acid; LOD: Limit of Detection; LOQ: Limit of Quantification.


The IUPAC name for Glimepiride is given as 3-Ethyl-4-methyl-N-[2-(4-{[(trans-4-methylcyclohexyl) carbamoyl] sulfamoyl} phenyl) ethyl]-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide (Figure 1). It is a solid having melting point of 207oC; it is insoluble in water [1]. It is very similar to Glipizide with the exclusion of their heterocyclic rings as an alternative of pyrazine ring originate in Glipizide, Glimepiride holds a pyrrolidine system. It is metabolized principally through oxidation of the alkyl side chain of the pyrrolidine, with a petty metabolic route involving acetylation of the amine [2]. It exerts its action by dropping blood glucose level by interfering with ATP sensitive k+ channels on pancreatic beta cells [3] (Figure 2).

Figure 1: Chemical structure of glimepiride.

Figure 2: Mechanism of action of Glimepiride.

Mode Of Action

The mechanism of action of Glimepiride in depressing blood glucose seems to be reliant on triggering the release of insulin from functioning pancreatic beta cells, and accumulating sensitivity of bordering tissues to insulin. Glimepiride likely impasses to ATP-sensitive potassium channel receptors on the pancreatic cell surface, dropping potassium conductance and triggering depolarization of the membrane. Membrane depolarization motivates calcium ion influx over voltage-sensitive calcium channels. This proliferates in intracellular calcium ion concentration convinces the secretion of insulin [3].

Metabolism Of Glimepiride

Glimepiride is completely metabolised by oxidation of the pendant methyl substitution on the cyclohexane ring to a Hydroxylmethyl metabolite (3a) and a carboxylic acid (2b). The Hydroxylmethyl metabolite consumes almost one third of the hypoglycaemic activity of the parent in an animal model, whereas the order was not active [4]. Glimepiride is pumped out of the body with a half-life of about 9 hours, and metabolites, but no parent drug found in both urine (60%) and feces (40%), with (3b) the prime species in urine and (3a) in feces [5]. The schematic pathway for metabolism of Glimepiride is shown in Figure 3.

Figure 3: Metabolism of GLIM.

Analytical Accounts On Glimepiride

The widespread literature survey exposed numerous analytical techniques viz. UV/Visible- Spectrophotometry, HPLC, HPTLC and UPLC-MS-MS (Figure 4) for the fortitude of GLIM in bulk and pharmaceutical formulations. The reported methods describe the estimation of GLIM in various dosage forms as single constituent and in combination with Metformin Hydrochloride, Pioglitazone, Dapagliflozin, Rosiglitazone Maleate, Voglibose, Ramipril Atorvastatin Gliclazide. Figure 4 spectacles different analytical methods implemented for estimation of GLIM.

Figure 4: Analytical accounts on glimepiride.

Pharmacopoeial Status

IP portrayed HPLC assay method consuming a stainless steel 25 cm x 4.0 mm, packed with endcapped octadecylsilane bonded to porous silica (4 μm), as a static phase and mobile phase comprised of a fusion of 50% volumes of a solution prepared by dissolving 0.5 g of sodium dihydrogen orthophosphate in 500 mL of water, adjusted to pH 2.5with Orthophosphoric acid and 50% volumes of acetonitrile, keeping the flow rate of 1 mL/min. Column effluent was scrutinized at 228 nm, and injection volume set at 20 μl [5].

Spectrophotometric Methods

Till the date lots of spectrophotometric methods have been accounted for the determination of Glimepiride alone and in combination. This review compiles six papers describing spectrophotometric methods for estimation of Glimepiride alone and eight papers for the same in combination [6-11]. Table 1 consists of spectrophotometric method for Glimepiride alone and Table 2 consist of spectrophotometric methods for Glimepiride in combination [12-19].

Sl. No. Compounds Matrix Method Detection (λ max) nm Solvent
1 GLIM Bulk drug and tablet [6] Simple UV spectrophotometric method 249 nm Chloroform
2 GLIM Bulk drug and combined tablet [7] Spectrophotometric method through ion-pair complex formation using bromocresol green 416 nm Na2CO3, chloroform
3 GLIM Bulk drug and tablet [8] UV-vis. Spectroscopy 231 nm NaOH
4 GLIM Bulk drug and tablet [9] Simple UV spectrophotometric method 226 nm Methanol
5 GLIM Bulk drug and tablet [10] Second order derivative UV spectrophotometry 268.2 and
271.8 nm
6 GLIM Bulk drug and tablet [11] UV spectrophotometric & HPLC 230 nm
(00 order)

Table 1: Spectrophotometric methods for analysis of glimepiride.

Sl. No. Drug Matrix Method Detection Solvent
1 Metformin hydrochloride and Glimepiride Bulk drug and tablet [12] UV-Visible spectrophotometry 233.2 (MET)
228.0 (GLI)
0.05 M KOH & water
2 Pioglitazone and
Tablet [13] Simultaneous estimation method (multiwavelength
238.0 nm
0.1 N NaOH
3 Metformin HCl and Glimepiride Bulk and Tablet Dosage Form [14] Simultaneous estimation method and AUC 236 (MET) 228 (GLI) Methanol
4 Dapagliflozin Propanediol And Glimepiride Synthetic mixture [15] Derivative spectroscopy and RP-HPLC 224 (DAPA)
5 Pioglitazone (PIO) and Glimepiride (GLIM) Bulk and Tablet Dosage Form [16] Simultaneous estimation method 216 (PIO)
225 (GLIM)
0.1N NaOH
6 Metformin Hydrochloride, Glimepiride
and Pioglitazone
Bulk and Tablet Dosage Form [17] First Generation Chemometric Methods 200-400 Methanol
7 Rosiglitazone maleate and glimepiride Tablet Dosage Form [18] Simultaneous Estimation Method 244 (GLI)
0.1N NaOH
8 glimepiride and metformin Tablet Dosage Form [19] Simultaneous Estimation Method and Derivative Spectroscopy 222 (GLI)  228 (MET) 0.1M NaOH

Table 2: Spectrophotometric methods for analysis of glimepiride in combination.

Sakala et al., conveyed a modest spectrophotometric scheme for determination of Glimepiride in tablet dosage form consuming chloroform as a solvent. The reported method involves the calculation of absorbance at 249 nm [1].

Abdul et al., settled a spectrophotometric scheme for analysis of Glimepiride in pure and its marketed preparation through formation of composite with Bromocresol green. The method encompasses the development of yellow ionpair complex among Bromocresol green reagent and Glimepiride. The modeled complexes were scrutinized at a wavelength of 416 nm against the blank prepared in identical fashion. It is stated that aliquots in the series of 0.981-9.812 μg/ml conform Beers law. (LOD) and (LOQ) are mentioned as 0.088 and 0.29 μg/ml, accordingly [7].

Dyade et al., outlined a spectrophotometric scheme for simultaneous estimation of Glimepiride and metformin hydrochloride consuming mutual tablet formulation via water and 0.5 M KOH as a solvent system. Separation was carried out by extraction of tablet triturate with chloroform and the rest of the residue with 0.5 M KOH. Analysis was performed at a wavelength of 233.2 nm for metformin and 228.0 nm for Glimepiride. It is prostrated that Glimepiride conforms Beers law in the concentration arrays from 5 to 30 mcg/ml [12]. Apart from Pharmacopoeial methods many HPLC methods have been reported the determination for GLIM alone and in combination. In current review, a sum of total six papers for estimation of GLIM alone are presented, while total sum of 11 papers are presented for estimation of GLIM in combination are presented [20-25]. The summary of the reported HPLC methods particularizing the mobile phase used for determination, sample matrix, �� max and linearity for GLIM alone is shown in Table 3 while the summary of the reported HPLC methods for GLIM in combination is shown in Table 4 [26-35].

Sl. No. Drug Matrix Method Stationary phase Mobile phase Detection
1 GLIM Tablet [20] RP-HPLC Hypersil C18 column (250 m×4.6 mm, 5 µm) ACN: potassium dihydrogen phosphate(0.02 M) buffer (60:40 v/v) 232 1.0 5.420
2 GLIM Rat serum
RP-HPLC LiChrosphere 100 RP 18 e (125×4.0 mm i.d, 5 µm) MeOH: Pot. dihydrogen orthophosphate (10 mM) buffer
(80:20 v/v)
230 1.0 5.5
3 GLIM Bulk drug  and tablet [22] Normal phase Chiral HPLC Chiralpak IC (250×4.6) mm, 5 µm n-Hexane: EtOH
228 0.6  
4 GLIM Tablet [23] Hydrophilic interaction liquid chromatography (HILIC). Waters Spherisorb S5NH2 column (250×4.6 mm, 5 µm;
Waters, Milford, MA)
ACN and Aq. Acetate buffer (5.0 mM)
228 1.0 4.6
5 GLIM Human serum [24] HPLC Agilent LiChrospher 100, C18 column,
5 µm, 250×4 mm I.D., with a 2 mm precolumn filter
ACN: water (containing GAA (0.1 mM,
50:50 v/v
228 0.7  
6 Glimepiride Bulk drug and tablet [25] RP-HPLC Octadecyl silane (ODS) column (250×4.6 mm) 5 µm acetonitrile: 0.2 M phosphate buffer (pH=7.4) 40:60 v/v 228 1.0 3.529

Table 3: HPLC methods for analysis of glimepiride (GLIM).

Sl. No. Drug Matrix Method Stationary phase Mobile phase Detection
F.R. R.T.
1 MET+
Bulk and Combined Tablet Dosage
Form [26]
Gradient RP-HPLC Inertsil ODS 3V (150×4.6 mm, i.d.,
5 µm) column
ACN: water 0.02 M phosphate buffer (50:50) 230 1.0 (MET)2.426
2 GLIM+PIO+MET Bulk and Combined Tablet Dosage
Form [27]
RP-HPLC Inertsil ODS-3 V (250 mm×4.6 mm, 5 µm)
buffer, acetonitrile, tetrahydrofuran (40:50:10). 228 1.7 5.043 (GLI)
3.977 (PIO)
1.342 (MET)
3 GLIM+ PIO.HCL+ MET.HCL Combined Tablet Dosage Form [28] RP-HPLC (XBridge C18, 250×4.6 mm; 5 µm Methanol: Phosphate Buffer: (60:40) 257 1.0 4.750 (MET),
7.083 (PIO) 11.367 (GLIM)
4 PIO+ GLIM Tablet Dosage Form [29] RP-HPLC Phenomenex Luna C18 column
(4.6×150 mm)
Acetonitrile: KH2PO4 buffer (60:40%v/v) (Ph6) 230 1.5 4.4 (PIO)
5 MET.
Bulk and Combined Tablet Dosage
Form [27]
RP-HPLC Hypersil BDS C18, 250×4.6 mm, 5 µm Methanol:0.02M KH2PO4 buffer in the ratio of 850:150 v/v , 210 0.8 3.920 (MET)
4.433 (RAM)
4.837 (GLIM)
6 MET+
Tablet Dosage Form [30] HPLC & UV Derivative
Spectrophotometric Methods
Phenomenex RP-C18
(150×4.6 mm, 5 µm)
ACN and phosphate buffer (pH 3)
(65: 35)
245 0.5 2.75 (MFN)
4.35 (PLZ)
8.75 (GLIM)
7 MET. HCl+ RAM+
Bulk and Combined Tablet Dosage
Form [31]
RP-HPLC Inertsil ODS C18, 150×4.6 mm, L1 packing, Methanol and pH 3.0 KH2PO4
Buffer(50:50) v/v
228 1.0 4.9929 (MET)
2.602 (RAM)
3.789 (GLIM)
8 GLIM+ ATR Human Serum [32] HPLC Inertsil C18 (25 cm, 4.6mm i.d.,
5 µm) at 30°C
ACN: water (containing 1%triethylamine)
55:45 v/v
230 1.0 9.80 (GLIM) 6.92 (ATN)
9 ROSI. Maleate + GLIM Combined Tablet Dosage Form [33] HPLC Hi Q Sil C18HS (250 mm×4.6 mm, 5.0 µm) Methanol:20 mM ammonium dihydrogen phosphate [78:22 (v/v); pH 3.85] 240 1.0 3.32 (ROSI)
8.42 (GLIM)
10 PIO+ GLIM Bulk and Combined Tablet Dosage
Form [34]
RP-HPLC Inertsil ODS (250×4.6 mm, 5µm) Acetonitrile and
Ammonium acetate (pH 4.5; 20mM)60:40 (v/v).
230 1.0  7.0 ± 0.1 (PIO)
10.2 ± 0.1
11 ROSI+ GLIM Human plasma [35] RP-HPLC 150×4.6 mm i.d., 5 µm particle size
C18 column
ACN :0.02 M phosphate buffer (pH 5)
(60: 40, V/V)
235 1.0 ROS (3.7), GLIM ( 4.66)

Table 4: HPLC methods for analysis of Glimepiride in combination.


Vaishali prostrated an RP-HPLC method for the assessment of Glimepiride (GLM) from bulk drug and Pharmaceutical formulation. Author spent a Hypersil C18 column (250 mm×4.6 mm, 5 μm) by isocratic elution. Mobile phase system is a blend of ACN: Buffer (60:40 v/v), with an aid of buffer comprises of 0.02 M Potassium Dihydrogen Phosphate buffer (KH2PO4) with a pH of 4.5 adjusted by OPA, keeping a constant flow rate of mobile phase as 1.0 mL/min and detection is archived by means of a UV detector at 232 nm wavelength. Drug GLIM was found to have retention time of 5.420 min. A linear calibration curve was obtained in the concentration series of 50 μg/mL to 150 μg/mL [20].

Neelima et al., settled a RP-HPLC scheme for the concurrent estimation of Metformin (MET), Voglibose (VOG) and Glimepiride (GLIM) in loose and in their collective tablet formulation, consuming an inertsil ODS 3V (150×4.6 mm, i.e. 5 μm) column as a static phase and 0.02 M Phosphate buffer balanced to pH 2.5 with an aid of dilute Orthophosphoric acid (solvent A) and ACN (solvent B) as a mobile phase at a flow rate of 1 mL/min. keeping wavelength of PDA detector at 230 nm. The drugs MET, VOG and GLIM shown RT at a time interval of 2.423, 8.191, and 11.708 min. correspondingly [26].


The present review illustrates various analytical approaches exercised for the appraisal of GLIM. Numerous investigation has been performed including HPLC, HPTLC (Table 5), UV/Vis-Spectroscopy, LC-MS/MS, UPLCMS/ MS etc. for estimation of GLIM in loose and in its collective pharmaceutical preparations and in plasma [36-42]. Liquid chromatography with UV detection has been found to be most deliberate for assessment of GLIM in bulk as well as pharmaceutical dosage forms, while hyphenated UPLS-MS/MS, LS-MS/MS methods are conveyed for determination of GLIM and its metabolite in plasma and other biological fluids (Table 6) [43-45]. Further, methods were reported for its pharmacokinetic as well as bioequivalence studies. Few chromatography methodologies like HPTLC and Stability-indicating HPLC and HPTLC are also reported in literature.

Sl. No. Drugs Matrix Method Stationary phase Mobile phase Detection
1 GLIM +MET.HCL Bulk drug [36] Stability Indicating HPTLC Silica gel 60F254 HPLC Plates 0.5% Amm. Sulphate: MeOH (7.5:2.5 v/v) 228 0.739 (GLIM)
2 PIO+ GLIM Tablet [37] HPTLC Silica gel 60F254 HPLC Plates
Toluene, Ethyl Acetate, MeOH And GAA (70:15:10:5 v/v/v/v). 235 0.42 (PIO)
0.279 (GLIM)
 3 ROSI+ GLIM Fixed Tablet Dosage Form [38] (HPTLC) densitometry Silica gel 60F254 HPLC Plates  MeOH: Toluene: Ethyl Acetate (1:8:1, v/v/v). 228 0.39 ± 0.03 (ROSI)
0.20 ± 0.04 (GLIM)
4 PIO+MET+ GLIM Tablet [39] HPTLC Silica gel 60F254 HPLC Plates ACN, MeOH, Propyl alcohol, And Amm. Acetate
(7:2:1:1 v/v)
240 0.83 (PIO),
0.21 (MET),
0.89 (GLIM)
5 ATR+ GLIM +MET Combined Dosage Form [40] HPTLC Silica gel 60F254 HPLC Plates Water, MeOH, Amm. Sulphate (3.5:3.5:12.6, v/v/v) 245 0.50 ± 0.01 (ATR),
0.65 ± 0.01 (GLIM),
0.33 ± 0.01) (MET)
6 MET.HCL+ ATR+ GLIM Bulk Drug and Formulation [41] HPTLC Silica gel 60F254 HPLC Plates Water, MeOH: Amm. Sulphate
(1: 1: 4 v/v/v).
237 0.37 ± 0.02 (MET)
0.59 ± 0.02 (ATV),
0.75 ± 0.02 (GLIM)
7 MET+GLIC+ GLIM Tablet [42] HPTLC Silica gel 60F254 HPLC Plates
(10×10 cm).
Amm. Sulphate (0.25%):
MeOH: Ethyl Acetate (10.0:2.5:2.5 v/v/v)
285 0.69 (MET)
0.39 (GLIM)

Table 5: HPTLC methods for analysis of Glimepiride in combination.

Drug Matrix Stationary phase Mobile phase Method Detection
Discussion FR/RT
01 GLIM+
Human plasma [43] ACE5C18 (50×4.6 mm, ACE, Scotland) column 0.1% formic acid: acetonitrile (30:70, v/v) LC-MS/MS MDS Sciex (Foster City, CA, USA) API-4000 mass spectrometer Linearity:
0.2-30 ng/mL(ATR)
1-250 ng/mL(GLIM)
FR:0.5 ml/min
RT: 1.91(ATR)
02 MET+
Human plasma [44] UPLCTM BEH C18 (100.0×2.1 mm, 1.7 µm) column ACN-2mM ammonium acetate (50:50, v/v) UPLC/Q-TOF-MS Tuneable MS detector. Linearity:
1-1000 ng/mL
03 GLIM+
Human plasma
Acquity UPLC BEH C18 column ACN-1% formic acid in water UPLC-MS/MS QTrap 5500 mass spectrometer Linearity:
2.5-300 ng/mL (GLIM)
ng/mL (FLU)

Table 6: LC-MS/MS methods for analysis of Glimepiride in combination.


Select your language of interest to view the total content in your interested language

Viewing options

Recommended Conferences
Post your comment

Share This Article

Flyer image
journal indexing image